Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Abaxis third quarter revenues increase 32% to $49.8 million

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2012.

31 Jan 2013

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient.

31 Jan 2013

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech, a member of the Roche Group, today announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated chronic lymphocytic leukemia (CLL).

31 Jan 2013

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS).

30 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

New study may help treat patients with multiple myeloma

A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.

25 Jan 2013

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide.

24 Jan 2013

Study may help predict which multiple myeloma patients will respond better to certain treatments

24 Jan 2013

KLF6-SV1 gene variant drives the spread of breast cancer

A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, and collaborators at the Mount Sinai School of Medicine and Erasmus Medical Center, have discovered a gene variant that drives the spread of breast cancer.

23 Jan 2013

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

23 Jan 2013

PathCentral announces roll-out of new pathology network

PathCentral, a technology-enabled company dedicated to the success of the international pathology community, and China-based Kindstar Globalgene Technology, Inc., today announced the roll-out of the PathCentral Pathology Network, an online professional pathology network that will enable Kindstar to access US pathologists and facilitate pathology consultations for more than 3,300 hospitals throughout China.

22 Jan 2013

Golden nanoparticle starves cancer cell to death

How do you annihilate lymphoma without using any drugs? Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol.

21 Jan 2013

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

19 Jan 2013

Penn Medicine to establish new center for treatment and research of blood diseases

Penn Medicine will establish the Philadelphia region's first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses.

18 Jan 2013

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development.

18 Jan 2013

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company researching a new class of glycobiology-based therapies for a broad range of diseases, today announced that it has completed enrolling patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate.

18 Jan 2013

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

A groundbreaking, international clinical trial of an iron chelation drug, deferiprone, to treat the rare and devastating neurodegenerative disease, pantothenate kinase-associated neurodegeneration (PKAN), began last month at the trial's only North American site, Children's Hospital & Research Center Oakland.

17 Jan 2013

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

NanoSmart Pharmaceuticals, a private biotechnology company, has entered into a research collaboration agreement with University of California Los Angeles (UCLA) to continue the development of NanoSmart's novel drug delivery platform for the treatment of cancer and other life-threatening diseases.

17 Jan 2013

Proteinuria common in canine lymphoma

Approximately a quarter of dogs with lymphoma have proteinuria, a much greater proportion than seen in healthy dogs, indicate research results.

16 Jan 2013

Hematology News and Research

Further Reading

Abaxis third quarter revenues increase 32% to $49.8 million

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

New study may help treat patients with multiple myeloma

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Study may help predict which multiple myeloma patients will respond better to certain treatments

KLF6-SV1 gene variant drives the spread of breast cancer

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

PathCentral announces roll-out of new pathology network

Golden nanoparticle starves cancer cell to death

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Penn Medicine to establish new center for treatment and research of blood diseases

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

Proteinuria common in canine lymphoma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo